Mountain View, Calif. -- MAP Pharmaceuticals, a Mountain View-based developer of inhaled drug therapies, said that it has raised $25.25 million in its third round of funding, led by Brookside Capital. All of the company's previous investors including the Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Bay City Capital and Skyline Ventures, also participated. MAP said that it plans to use the proceeds to further the development of its two top drug candidates for the treatment of asthma and migraines.
http://www.mappharma.com/news/index.html
Sponsors
Listings
Notices
Recent Posts
- San Jose-Based Nanosolar Raises $70 Million in New Funding
- S.F.-Based Thayer Ventures to Invest in Hospitality Technology Startups
- Mountain View-Based Google Acquires Trust-Score Service KikScore
- OneSpin Solutions Lands Funding, Names New CEO
- Palo Alto-Based Diffbot Lands $2 Million in Funding from Tech Execs
- Opnet Technologies Acquires Redwood City-Based Clarus Systems
- Fremont-Based Redwood Systems Lands $11.75M in Third Round
- Redwood City-Based Shutterfly Acquires Photoccino
- Danaher to Acquire San Mateo-Based VSS Monitoring
- Founder Trip Hawkins to Depart as CEO of Digital Chocolate
Editor: Rich Scherr
For news tips and editorial issues,
contact editor Rich Scherr at
rich@techwiremedia.com
For advertising information, contract
Parul Nath at parul@techwiremedia.com
A Service of Tech Wire Media
Archives
- May 27, 2012 - June 2, 2012
- May 20, 2012 - May 26, 2012
- May 13, 2012 - May 19, 2012
- April 29, 2012 - May 5, 2012
- April 22, 2012 - April 28, 2012
- April 15, 2012 - April 21, 2012
- April 8, 2012 - April 14, 2012
- April 1, 2012 - April 7, 2012
- March 25, 2012 - March 31, 2012
- March 18, 2012 - March 24, 2012
